Halozyme Therapeutics (HALO) Receives Price Target

Halozyme Therapeutics (HALO) : Average target price received by Halozyme Therapeutics (HALO) is $12.58 with an expected standard deviation of $5.08. The most aggressive target on the stock is $16, whereas the most downbeat target is $7. 3 financial analysts are currently covering the stock.

Halozyme Therapeutics (HALO) : 4 analysts are covering Halozyme Therapeutics (HALO) and their average rating on the stock is 1.75, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. 1 more analyst has given the stock a Sell recommendation.


Halozyme Therapeutics (NASDAQ:HALO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.85 and $9.77 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.02. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.97, notching a gain of 1.73% for the day. The total traded volume was 928,395 . The stock had closed at $9.80 on the previous day.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *